CARTIMMUNE: a Single-Center Study of Patients with Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs KYV-101 (Primary) ; Cyclophosphamide; Fludarabine
Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Antisynthetase syndrome; Diffuse scleroderma; Lupus nephritis; Myositis
Focus Adverse reactions
Acronyms CARTIMMUNE

27 Feb 2025 Status changed from recruiting to active, no longer recruiting.
16 Oct 2024 Planned End Date changed from 1 Jun 2028 to 1 Aug 2028.
16 Oct 2024 Planned primary completion date changed from 1 Jun 2028 to 1 Aug 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com